Amyloid imaging in clinical trials

The possibility to map amyloid-beta, the Alzheimer’s disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid burden, particularly when potential amyloid-lowering drugs are at play, requires accurate an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ossenkoppele, Rik, Prins, Niels D, van Berckel, Bart NM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978734/
https://www.ncbi.nlm.nih.gov/pubmed/23953396
http://dx.doi.org/10.1186/alzrt195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978734/
https://www.ncbi.nlm.nih.gov/pubmed/23953396
http://dx.doi.org/10.1186/alzrt195

Ejemplares similares